|
Sonoma Pharmaceuticals Inc (SNOA) |
|
Sonoma Pharmaceuticals Inc
SNOA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Sonoma Pharmaceuticals Inc growth rates, revenue grew
by 6.59 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 317
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by
Sonoma Pharmaceuticals Inc net loss deacreased by in III. Quarter 2023 year on year, Sonoma Pharmaceuticals Inc net loss increased by -55.34 % in III. Quarter 2023 year on year,
• More on SNOA's Growth
|
|
Sonoma Pharmaceuticals Inc current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.
Sonoma Pharmaceuticals Inc PEG ratio is at -0
|
Company |
|
PE TTM
|
Industry |
268.41 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.71.
• More on SNOA's Valuation
|
|
|
|
|
Sonoma Pharmaceuticals Inc current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.
Sonoma Pharmaceuticals Inc PEG ratio is at -0
|
Company |
|
PE TTM
|
Industry |
268.41 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.71.
| | | |